Identification of prognostic molecular biomarkers in 157 HPV-positive and HPV-negative squamous cell carcinomas of the oropharynx.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ genetics
Carcinoma, Squamous Cell
/ genetics
Chromosomes, Human
/ genetics
Female
Gene Expression Regulation, Neoplastic
Gene Regulatory Networks
Humans
Male
Middle Aged
Mutation
Oropharyngeal Neoplasms
/ genetics
Papillomavirus Infections
/ genetics
Prognosis
Survival Analysis
Exome Sequencing
/ methods
NOTCH1
SOX2
HPV
oropharynx
squamous cell carcinoma
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 12 2019
01 12 2019
Historique:
received:
09
02
2019
revised:
23
04
2019
accepted:
30
04
2019
pubmed:
17
5
2019
medline:
1
2
2020
entrez:
17
5
2019
Statut:
ppublish
Résumé
The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has been increasing due to high-risk HPV infection. We explored the significance of genetic alterations in HPV-positive (HPV-P) and HPV-negative (HPV-N) OPSCC patients on long-term outcome. A total of 157 cases of primary resected OPSCC diagnosed from 1978 to 2005 were subjected to a targeted exome sequencing by MSK-IMPACT™ interrogating somatic mutations in 410 cancer-related genes. Mutational profiles were correlated to recurrence and survival outcomes. OPSCC included 47% HPV-positive (HPV-P) and 53% HPV-negative (HPV-N) tumors arising in the base of tongue (BOT, 43%), palatine tonsil (30%) and soft palate (SP, 27%). HPV negative status, SP location and smoking were associated with poorer outcome. Poorer overall survival was found in NOTCH1-mutated HPV-P (p = 0.039), and in SOX2-amplified HPV-N cases (p = 0.036). Chromosomal arm gains in 8p and 8q, and 16q loss were more common in HPV-P (p = 0.005, 0.04 and 0.01, respectively), while 9p, 18q and 21q losses were more frequent in HPV-N OPSCC (p = 0.006, 0.002 and 0.01, respectively). Novel, potentially functional JAK3, MYC and EP300 intragenic deletions were found in HPV-P, and FOXP1, CDKN2A, CCND1 and RUNX1 intragenic deletions and one FGFR3 inversion were detected in HPV-N tumors. HPV-N/TP53-wild-type OPSCC harbored recurrent mutations in NOTCH1/3/4 (39%), PIK3CA, FAT1 and TERT. In comparison to their oral and laryngeal counterparts, HPV-N OPSCC were genetically distinct. In OPSCC, HPV status, tumor subsite and smoking determine outcome. Risk-stratification can be further refined based on the mutational signature, namely, NOTCH1 and SOX2 mutation status.
Identifiants
pubmed: 31093971
doi: 10.1002/ijc.32412
pmc: PMC7595146
mid: NIHMS1635629
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3152-3162Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA172012
Pays : United States
Informations de copyright
© 2019 UICC.
Références
Science. 2011 Aug 26;333(6046):1157-60
pubmed: 21798893
Clin Cancer Res. 2018 Dec 15;24(24):6308-6318
pubmed: 30087145
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28890946
Nat Rev Cancer. 2011 Jan;11(1):9-22
pubmed: 21160525
J Natl Cancer Inst. 2000 May 3;92(9):709-20
pubmed: 10793107
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Am J Surg Pathol. 2011 Sep;35(9):1343-50
pubmed: 21836494
Stem Cell Reports. 2015 Dec 8;5(6):1210-1225
pubmed: 26527383
N Engl J Med. 2007 Dec 20;357(25):2552-61
pubmed: 18094376
J Natl Cancer Inst. 2008 Feb 20;100(4):261-9
pubmed: 18270337
Ann Surg Oncol. 2015 Dec;22(13):4411-21
pubmed: 25801358
J Clin Oncol. 2015 Mar 10;33(8):836-45
pubmed: 25667292
Clin Cancer Res. 2015 Feb 1;21(3):632-41
pubmed: 25056374
Carcinogenesis. 2014 Jul;35(7):1636-42
pubmed: 24743512
Ann Oncol. 2016 Dec;27(12):2262-2268
pubmed: 27681865
Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75
pubmed: 15734974
J Mol Diagn. 2015 Sep;17(5):576-82
pubmed: 26165824
Nucleic Acids Res. 2016 Sep 19;44(16):e131
pubmed: 27270079
Clin Cancer Res. 2014 Feb 1;20(3):701-10
pubmed: 24277457
Laryngoscope Investig Otolaryngol. 2017 Jan 17;2(1):10-18
pubmed: 28894817
Int J Cancer. 2011 Apr 1;128(7):1596-605
pubmed: 20499310
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Cancer. 2013 Jan 1;119(1):81-9
pubmed: 22736261
Science. 2011 Aug 26;333(6046):1154-7
pubmed: 21798897
Mol Oncol. 2015 Oct;9(8):1704-19
pubmed: 26040981
JAMA Oncol. 2017 Feb 1;3(2):244-255
pubmed: 27442865
Br J Cancer. 2016 Jan 19;114(2):199-206
pubmed: 26742007
Int J Clin Exp Med. 2014 Dec 15;7(12):5010-20
pubmed: 25664000
New Microbiol. 2014 Apr;37(2):129-43
pubmed: 24858640
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821